Schwab Charles Investment Management Inc. Acquires 4,485 Shares of Global Blood Therapeutics Inc (GBT)

Schwab Charles Investment Management Inc. lifted its holdings in shares of Global Blood Therapeutics Inc (NASDAQ:GBT) by 3.0% in the third quarter, Holdings Channel reports. The institutional investor owned 154,119 shares of the company’s stock after purchasing an additional 4,485 shares during the quarter. Schwab Charles Investment Management Inc.’s holdings in Global Blood Therapeutics were worth $4,786,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Emory University bought a new stake in shares of Global Blood Therapeutics during the 2nd quarter valued at about $1,442,000. Citigroup Inc. grew its position in shares of Global Blood Therapeutics by 1,544.9% during the 2nd quarter. Citigroup Inc. now owns 87,819 shares of the company’s stock valued at $2,402,000 after buying an additional 82,480 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Global Blood Therapeutics by 211.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 317,571 shares of the company’s stock valued at $8,686,000 after buying an additional 215,690 shares during the last quarter. State Board of Administration of Florida Retirement System grew its position in shares of Global Blood Therapeutics by 38.6% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 17,759 shares of the company’s stock valued at $551,000 after buying an additional 4,950 shares during the last quarter. Finally, Nexthera Capital LP grew its position in shares of Global Blood Therapeutics by 66.3% during the 2nd quarter. Nexthera Capital LP now owns 340,100 shares of the company’s stock valued at $9,302,000 after buying an additional 135,600 shares during the last quarter. 85.72% of the stock is owned by institutional investors and hedge funds.

Several research firms have commented on GBT. BidaskClub upgraded shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, September 27th. Needham & Company LLC set a $51.00 target price on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 24th. Oppenheimer set a $53.00 target price on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Zacks Investment Research cut shares of Global Blood Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, October 16th. Finally, HC Wainwright set a $73.00 target price on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Monday, December 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have given a buy rating to the company’s stock. Global Blood Therapeutics has a consensus rating of “Buy” and an average target price of $62.07.

In related news, major shareholder Perceptive Advisors Llc purchased 175,000 shares of Global Blood Therapeutics stock in a transaction dated Tuesday, December 19th. The stock was bought at an average cost of $38.00 per share, with a total value of $6,650,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Charles J. Homcy sold 70,000 shares of the company’s stock in a transaction that occurred on Friday, October 27th. The stock was sold at an average price of $33.97, for a total transaction of $2,377,900.00. Following the completion of the sale, the director now directly owns 83,328 shares of the company’s stock, valued at $2,830,652.16. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 88,500 shares of company stock valued at $3,023,000. Company insiders own 5.30% of the company’s stock.

Global Blood Therapeutics Inc (GBT) opened at $47.15 on Wednesday. Global Blood Therapeutics Inc has a 1 year low of $14.70 and a 1 year high of $48.85. The company has a market cap of $2,170.00 and a PE ratio of -18.49.

Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.04). During the same period in the prior year, the business earned ($0.58) EPS. sell-side analysts forecast that Global Blood Therapeutics Inc will post -2.54 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/01/10/schwab-charles-investment-management-inc-acquires-4485-shares-of-global-blood-therapeutics-inc-gbt.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics Inc (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit